The Latest Breaking News from Sanofi

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

With investors concerned about overall economic stability amid the Trump administration's tariff impact, they're not in a particularly generous mood. That may be the lesson learned the hard way by global pharmaceutical giant Sanofi SA (NASDAQ:SNY). Despite delivering an earnings report that offered an encouraging view, it wasn't a perfect…

Sanofi SA (NASDAQ:SNY) reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.

Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported second-quarter 2025 adjusted earnings of $5.36 per share, beating the street view of $5.23.

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, U.K.

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus vaccines and add a non-mRNA vaccine to its pipeline.

For more than a century, type 1 diabetes has meant one thing: a lifetime administering insulin. But for the first time, science is breaking that paradigm – not by managing the disease, but by intercepting it before symptoms even appear.

The Dow Jones fell modestly Monday amid U.S.-China tensions. Palantir and Tesla moved near buy points. Nucor jumped on Trump tariffs.